Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-21-013939
Filing Date
2021-06-09
Accepted
2021-06-09 19:00:43
Documents
1
Period of Report
2021-06-09

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3236
  Complete submission text file 0001493152-21-013939.txt   4821
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Issuer) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E, SUITE 310 SEATTLE WA 98102
Business Address
Kenney Richard T (Reporting) CIK: 0001606653 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35570 | Film No.: 211006407